Elsevier Editorial System(tm) for Vaccine
Manuscript Draft

Manuscript Number:

Title: ADVANCE system testing: can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination

Article Type: SI: ADVANCE

Keywords: pertussis vaccination; pertussis-related complications; database study; feasibility study; children; pertussis incidence

Corresponding Author: Dr. Daniel Weibel,

Corresponding Author's Institution: bVACCINE.GRID Foundation

First Author: Daniel Weibel

Order of Authors: Daniel Weibel; Caitlin Dood; Olivia Mahaux; Francois Haguinet; Tom De Smedt; Talita Duarte-Salles; Gino Picelli; Lara Tramontan; Giorgia Danieli; Ana Correa; Chris McGee; Elisa Martín-Merino; Consuelo Huerta; Klara Berencsi; Hanne-Dorthe Emborg; Kaatje Bollaerts; Vincent Bauchau; Lina Titievsk; Miriam Sturkenboom

Abstract: Introduction
The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) public-private collaboration, aimed to develop and test a system for rapid benefit-risk monitoring of vaccines using healthcare databases in Europe. The objective of this proof-of-concept (POC) study was to test the feasibility of the ADVANCE system to generate incidence rates (IRs) per 1000 person-years and incidence rate ratios (IRRs) for risks associated with whole cell- (wP) and acellular- (aP) pertussis vaccines, occurring in event-specific risk windows in children prior to their pre-school-entry booster.
Methods
The study population comprised almost 5.1 million children aged 1 month to <6 years vaccinated with wP or aP vaccines during the study period from 1 January 1990 to 31 December 2015. Data from two Danish hospital databases (AUH and SSI) and five primary care (PC) databases from, UK (THIN and RCGP RSC), Spain (SIDIAP and BIFAP) and Italy (Pedianet) were analysed. Database-specific IRRs between risk vs. non-risk periods were estimated in a self-controlled case series study and pooled using random-effects meta-analyses.
Results
The overall IRs were: fever, 58.2 (95% CI: 58.1; 58.3); convulsions, 7.6 (95% CI: 7.6; 7.7); persistent crying, 3.9 (95% CI: 3.8; 3.9), injection-site reactions, 2.2 (95% CI 2.1; 2.2), hypotonic hypo-responsive episode (HHE), 0.4 (95% CI: 0.4; 0.4), and somnolence: 0.3 (95% CI: 0.3; 0.3). The pooled IRRs for persistent crying, fever, and ISR, adjusted for age and healthy vaccinee period were higher after wP vs. aP vaccination, and lower for convulsions, for all doses. The IRR for HHE was slightly lower for wP than aP, while wP was associated with somnolence only for dose 1 and dose 3 compared with aP.
Conclusions

The estimated IRs and IRRs were comparable with published data, therefore demonstrating that the ADVANCE system was able to assess vaccine safety data for wP and aP vaccination.

Dr Gregory A Poland
Editor-in-Chief, Vaccine

20 December 2018

Dear Dr Poland

We are pleased to submit our paper '*ADVANCE system testing: can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination*' to your Journal, Vaccine for the ADVANCE supplement. This paper describes the proof-of-concept study assessing the ADVANCE system to estimate the risks associated with pertussis vaccination. It is the sixth of the series of 10 papers that will be included in the supplement.

On behalf of all co-authors

Dr Daniel Weibel

***Author Agreement**

I, Dr. Daniel Weibel, declare that all authors have seen and approved the final version of the manuscript being submitted. We warrant that the article is our original work that has not been previously published and is not under consideration for publication elsewhere

Dr Daniel Weibel

***Suggested Reviewers**

Name	Institute	email
Tom Shimabukuro	US CDC	ayv6@cdc.gov
Frank Destefano	US CDC	fxd1@cdc.gov
Wan-Ting Huang	Taiwan CDC	pecuchet@gmail.com
Silvia Pérez Vilar	US FDA	Silvia.PerezVilar@fda.hhs.gov

***Declaration of Interest Statement**

Declaration of interests

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Caitlin Dodd, Talita Duarte-Salles, Gino Picelli, Lara Tramontan, Giorgia Danieli, Ana Correa, Chris McGee, Elisa Martín-Merino, Consuelo Huerta, Hanne-Dorthe Emborg, Kaatje Bollaerts, Klara Berencsi declared no conflicts of interest. Daniel Weibel declared personal fees from GSK outside the submitted work. Olivia Mahaux, Francois Haguinet and Vincent Bauchau declared that they are employed by GSK and hold shares from GSK. Lina Titievsky declared that she is employed Pfizer and holds stocks from Pfizer. Miriam Sturkenboom declared that she has received grants from Novartis, CDC and the Bill & Melinda Gates Foundation outside the submitted work.

Highlights

- We tested the ADVANCE system workflows and methods for assessing vaccine benefit-risk
- We evaluated the use of European healthcare databases to assess pertussis vaccine reactogenicity
- Estimates differed based on where the data originate, i.e. in a primary care or hospital setting
- Primary care databases were more suited for milder reactogenicity events than hospital databases
- European healthcare databases can be used to generate reliable estimates for vaccine safety events

ABSTRACT

Introduction

The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) public-private collaboration, aimed to develop and test a system for rapid benefit-risk monitoring of vaccines using healthcare databases in Europe. The objective of this proof-of-concept (POC) study was to test the feasibility of the ADVANCE system to generate incidence rates (IRs) per 1000 person-years and incidence rate ratios (IRRs) for risks associated with whole cell- (wP) and acellular- (aP) pertussis vaccines, occurring in event-specific risk windows in children prior to their pre-school-entry booster.

Methods

The study population comprised almost 5.1 million children aged 1 month to <6 years vaccinated with wP or aP vaccines during the study period from 1 January 1990 to 31 December 2015. Data from two Danish hospital databases (AUH and SSI) and five primary care (PC) databases from, UK (THIN and RCGP RSC), Spain (SIDIAP and BIFAP) and Italy (Pedianet) were analysed. Database-specific IRRs between risk vs. non-risk periods were estimated in a self-controlled case series study and pooled using random-effects meta-analyses.

Results

The overall IRs were: fever, 58.2 (95% CI: 58.1; 58.3); convulsions, 7.6 (95% CI: 7.6; 7.7); persistent crying, 3.9 (95% CI: 3.8; 3.9), injection-site reactions, 2.2 (95% CI 2.1; 2.2), hypotonic hypo-responsive episode (HHE), 0.4 (95% CI: 0.4; 0.4), and somnolence: 0.3 (95% CI: 0.3; 0.3). The pooled IRRs for persistent crying, fever, and ISR, adjusted for age and healthy vaccinee period were higher after wP vs. aP vaccination, and lower for convulsions, for all doses. The IRR for HHE was slightly lower for wP than aP, while wP was associated with somnolence only for dose 1 and dose 3 compared with aP.

Conclusions

The estimated IRs and IRRs were comparable with published data, therefore demonstrating that the ADVANCE system was able to assess vaccine safety data for wP and aP vaccination.

ADVANCE system testing: can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination

Daniel Weibel[a,b], Caitlin Dodd[a,c], Olivia Mahaux[d], Francois Haguinet[d], Tom De Smedt[e], Talita Duarte-Salles[f], Gino Picelli[g], Lara Tramontan[g], Giorgia Danieli[g], Ana Correa[h], Chris McGee[h,i], Elisa Martín-Merino[j], Consuelo Huerta[j], Klara Berencsi[kl1], Hanne-Dorthe Emborg[l], Kaatje Bollaerts[e], Vincent Bauchau[d], Lina Titievsky[m] and Miriam Sturkenboom[b,c,e*]

[a]Erasmus University Medical Center, Post box 2040, 3000 CA Rotterdam, Netherlands (d.weibel@erasmusmc.nl; caitlinndodd@gmail.com)

[b]VACCINE.GRID Foundation, Spitalstrasse 33, Basel, Switzerland (d.weibel@vaccinegrid.org; m.c.j.sturkenboom@umcutrecht.nl)

[c]Julius Center, University Medical Center Utrecht, Utrecht, Netherlands (caitlinndodd@gmail.com; m.c.j.sturkenboom@umcutrecht.nl)

[d]GSK, Av. Fleming 20, 1300, Wavre, Belgium (olivia.x.mahaux@gsk.com; francois.f.haguinet@gsk.com; vincent.g.bauchau@gsk.com)

[e]P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001 Heverlee, Belgium(tom.desmedt@p-95.com; kaatje.bollaerts@p-95.com; m.c.j.sturkenboom@umcutrecht.nl)

[f]Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain (tduarte@idiapjgol.org)

[g]Epidemiological Information for Clinical Research from an Italian Network of Family Paediatricians (PEDIANET), Padova, Italy (g.picelli@virgilio.it; ltramontan@consorzioarsenal.it; gdanieliconsorzioarsenal@gmail.com)

[h]University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom (accorrea1@googlemail.com; c.mcgee@surrey.ac.uk)

[1] Current affiliation: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

[i]Royal College of General Practitioners Research and Surveillance Centre, 30 Euston Square, London NW1 2FB, UK (c.mcgee@surrey.ac.uk)

[j]Base de Datos Para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP), Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain (emartinm@aemps.es; chuerta@aemps.es)

[k]Aarhus University Hospital, Olof Palmes Alle 43-45, Aarhus, DK-8200, Denmark (klara.berencsi@ndorms.ox.ac.uk)

[l]Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Artillerivej 5, DK-2300, Copenhagen, Denmark (hde@ssi.dk)

[m]Pfizer Inc., New York, NY (lina.titievsky@pfizer.com)

***Corresponding author**: Miriam CJM Sturkenboom, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands; email: m.c.j.sturkenboom@umcutrecht.nl; phone: +31 657 831 983

ADVANCE system testing: can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination

Daniel Weibel[a,b], Caitlin Dodd[a,c], Olivia Mahaux[d], Francois Haguinet[d], Tom De Smedt[e], Talita Duarte-Salles[f], Gino Picelli[g], Lara Tramontan[g], Giorgia Danieli[g], Ana Correa[h], Chris McGee[h,i], Elisa Martín-Merino[j], Consuelo Huerta[j], Klara Berencs[kl1], Hanne-Dorthe Emborg[l], Kaatje Bollaerts[e], Vincent Bauchau[d], Lina Titievsky[m] and Miriam Sturkenboom[b,c,e*]

[a]Erasmus University Medical Center, Post box 2040, 3000 CA Rotterdam, Netherlands (d.weibel@erasmusmc.nl; caitlinndodd@gmail.com)

[b]VACCINE.GRID Foundation, Spitalstrasse 33, Basel, Switzerland (d.weibel@vaccinegrid.org; m.c.j.sturkenboom@umcutrecht.nl)

[c]Julius Center, University Medical Center Utrecht, Utrecht, Netherlands (caitlinndodd@gmail.com; m.c.j.sturkenboom@umcutrecht.nl)

[d]GSK, Av. Fleming 20, 1300, Wavre, Belgium (olivia.x.mahaux@gsk.com; francois.f.haguinet@gsk.com; vincent.g.bauchau@gsk.com)

[e]P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001 Heverlee, Belgium(tom.desmedt@p-95.com; kaatje.bollaerts@p-95.com; m.c.j.sturkenboom@umcutrecht.nl)

[f]Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain (tduarte@idiapjgol.org)

[g]Epidemiological Information for Clinical Research from an Italian Network of Family Paediatricians (PEDIANET), Padova, Italy (g.picelli@virgilio.it; ltramontan@consorzioarsenal.it; gdanieliconsorzioarsenal@gmail.com)

[h]University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom (accorrea1@googlemail.com; c.mcgee@surrey.ac.uk)

[1] Current affiliation: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

[i]Royal College of General Practitioners Research and Surveillance Centre, 30 Euston Square, London NW1 2FB, UK (c.mcgee@surrey.ac.uk)

[j]Base de Datos Para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP), Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain (emartinm@aemps.es; chuerta@aemps.es)

[k]Aarhus University Hospital, Olof Palmes Alle 43-45, Aarhus, DK-8200, Denmark (klara.berencsi@ndorms.ox.ac.uk)

[l]Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Artillerivej 5, DK-2300, Copenhagen, Denmark (hde@ssi.dk)

[m]Pfizer Inc., New York, NY (lina.titievsky@pfizer.com)

***Corresponding author**: Miriam CJM Sturkenboom, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands; email: m.c.j.sturkenboom@umcutrecht.nl; phone: +31 657 831 983

Abstract

Introduction

The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) public-private collaboration, aimed to develop and test a system for rapid benefit-risk monitoring of vaccines using healthcare databases in Europe. The objective of this proof-of-concept (POC) study was to test the feasibility of the ADVANCE system to generate incidence rates (IRs) per 1000 person-years and incidence rate ratios (IRRs) for risks associated with whole cell- (wP) and acellular- (aP) pertussis vaccines, occurring in event-specific risk windows in children prior to their pre-school-entry booster.

Methods

The study population comprised almost 5.1 million children aged 1 month to <6 years vaccinated with wP or aP vaccines during the study period from 1 January 1990 to 31 December 2015. Data from two Danish hospital databases (AUH and SSI) and five primary care (PC) databases from, UK (THIN and RCGP RSC), Spain (SIDIAP and BIFAP) and Italy (Pedianet) were analysed. Database-specific IRRs between risk vs. non-risk periods were estimated in a self-controlled case series study and pooled using random-effects meta-analyses.

Results

The overall IRs were: fever, 58.2 (95% CI: 58.1; 58.3); convulsions, 7.6 (95% CI: 7.6; 7.7); persistent crying, 3.9 (95% CI: 3.8; 3.9), injection-site reactions, 2.2 (95% CI 2.1; 2.2), hypotonic hypo-responsive episode (HHE), 0.4 (95% CI: 0.4; 0.4), and somnolence: 0.3 (95% CI: 0.3; 0.3). The pooled IRRs for persistent crying, fever, and ISR, adjusted for age and healthy vaccinee period were higher after wP vs. aP vaccination, and lower for convulsions, for all doses. The IRR for HHE was slightly lower for wP than aP, while wP was associated with somnolence only for dose 1 and dose 3 compared with aP.

Conclusions

The estimated IRs and IRRs were comparable with published data, therefore demonstrating that the ADVANCE system was able to assess vaccine safety data for wP and aP vaccination.

Keywords: Pertussis vaccination; pertussis-related risk; database study; feasibility study; children

1. Introduction

The ADVANCE public-private collaboration aims to develop and test a system for rapid benefit-risk (B/R) assessment and monitoring of vaccines using health care databases in Europe and is following the distributed network approach that has been successful in several post-licensure vaccine safety studies [1, 2]. Details on the rationale and system have been described elsewhere in this supplement [3, 4]. Proof of concept (POC) studies were designed to test the system by assessing the feasibility of transforming data into evidence that would support B/R monitoring of vaccines. The aim of this study was to test the system's ability to generate results that could be benchmarked against other sources, not to generate new evidence. The POC studies addressed the comparative B/R of whole cell pertussis (wP) and acellular pertussis (aP) containing vaccines in children. The switch from wP to aP vaccines was used as a proxy for the introduction of a new vaccine, as an example of one of the scenarios where the ADVANCE system could be used in the future.

In this paper, we report the results from the comparison of safety outcomes after wP and aP vaccination, selected based on a literature review, which were used as input for the B/R analysis [5].

2. Methods

2.1. Study design and setting

A multi-database retrospective dynamic cohort study was conducted to estimate incidence rates (IRs) of specific safety outcomes after wP and aP vaccinations (risk period) and in a non-risk period. A self-controlled case series (SCCS) method, which uses only individuals with the event of interest, was used to estimate incidence rates (IRs) and incidence rate ratios (IRRs) for events of interest in defined risk periods after vaccination with wP- and aP-containing vaccines versus reference periods [6, 7].

2.2. Data sources

Data were obtained from seven healthcare databases that passed the fit for purpose assessment in 2016 and that agreed to participate in the ADVANCE project (**Table 1**) [8]. This assessment included the evaluation of incidences of several health outcomes, population indicators and vaccine information in the databases [8, 9]. There were two databases from Denmark: the regional Aarhus (AUH) and national Statens Serum Institute (SSI) hospital discharge databases which were linked to vaccination registries; two primary care medical record databases from Spain: Database for Pharmacoepidemiological Research in Primary Care (BIFAP) and the Information System for Research in Primary Care (SIDIAP); two primary care medical record databases from the UK: the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) database and The Health Improvement Network (THIN); and one family paediatrician database from an Italian network of family paediatricians that was linked to the Veneto region vaccination registry: PEDIANET [8, 10]. Data extraction, management, transformation, sharing, and analyses followed the ADVANCE system workflows and methodology [4].

2.3. Study population and follow-up

The study population comprised all children registered in the databases aged between one month and <6 years. Follow-up started either with the start of the study period (1 January 1990) or when valid data (database specific) were available, or the date children were aged one month, whichever was the latest. The end of follow-up was defined as the earliest of the following dates: the end of the study period (31 December 2015) or the date of the first occurrence of any of the following: pre-school-entry pertussis booster, 6th birthday, transferring out of the database, date of last data recorded, or death.

2.4. Pertussis vaccination exposure

The exposure of interest was vaccination with wP- or aP-containing vaccines by dose. Databases generally provided pertussis vaccine information coded as wP- or aP-containing vaccines. If pertussis vaccines were not coded specifically into wP or aP, we used the date of the switch to assign the pertussis vaccine type. We included a transition period (during the switch from wP to aP vaccine) in which pertussis vaccines were coded as 'unknown' (uP). For databases that did not have reliable information about the dose, we imputed dose information based on the local immunisation schedule using the recommended age of vaccination as imputation rule. This was done for 2% of all vaccinations in BIFAP and for 2.8% in SSI [11].

2.5. Outcomes

The selection of the study outcomes of interest was based on events that have been reported to be related with wP or aP vaccination in trials or studies [12-15]. These events were: persistent crying, hypotonic hypo-responsive episode (HHE), somnolence, fever, generalised and febrile convulsions/seizures, extensive limb swelling, and injection-site reactions (ISRs; including limb swelling). Whenever available, we used Brighton Collaboration case definitions to define the outcomes of interest [16-21]. Cases were identified from the electronic healthcare databases using codes and text (**Online Supplement Table 1**) [22]. The codes for different terminologies were obtained using the Codemapper manual review of the data access providers and harmonization was conducted using a standardised quality workflow [4, 23-25]. Based on expert opinion, post-aP or -wP vaccination exposure risk windows for each dose were defined as 0-24 hours for persistent crying, 0-48 hours for HHE and somnolence, 0-72 hours for generalised fever and febrile convulsions/seizures, and 0-7 days for ISR including limb swelling.

2.6. Statistical analyses

We estimated IRs and IRRs for all databases by vaccine type and dose. Person-time of follow-up was categorised as during risk window or outside risk window and was not censored at the occurrence of an event, thus allowing each child to experience more than one event. Events were considered recurrent (i.e., counted as two separate events) if they were at least seven days apart. Follow-up time was classified by calendar year, age (months) and the different risk windows for each child in the cohort. This person-time was used as the denominator for the IR estimations and their 95% confidence intervals (CIs) were calculated using a Poisson distribution [26]. The IRs are presented as IRs within the risk period, outside the risk period (baseline IRs), and as overall IRs which included both risk and baseline periods.

For the SCCS analyses, follow-up was calculated from cohort entry for individuals without recorded pertussis vaccine exposure or one month before the first recorded pertussis vaccine exposure until one month after the last pertussis vaccine exposure for individuals with recorded pertussis vaccine exposure (Figure 1). The non-risk period excluded the week before vaccination for the SCCS analyses to account for a potential healthy vaccinee effect just prior to vaccination. The SCCS models included age (in months) as a time-varying covariate, and all available aP or wP vaccine doses as exposure. The IRRs were adjusted for age in months and for the healthy vaccinee period. Random effects meta-analyses were performed by vaccine type and dose [27]. For wP, only data from the UK was used for the meta-analyses as the databases from the other countries contained little wP information due to their earlier switch from wP to aP [11]. Study heterogeneity was assessed by the chi-squared test for heterogeneity and quantified using the I^2 statistic.

We used SAS version 9.4 for the calculation of IRs and IRRs. SAS programs authored by Bart Spiessens and updated by Francois Haguinet were used for SCCS analyses. The meta-analyses were conducted using R.

2.7. Ethical considerations

The study protocol was approved by the approval committee of the local database and the ADVANCE steering committee. It was registered in the ENCePP registry (EUPAS13779) [28].

3. Results

3.1. Study population

We included data from seven European healthcare databases with a total source population of 38,599,335 persons (**Table 1**). The main reason for exclusion was outside age range during the study period. The study population comprised just over 5 million children aged <6 years, with 13,635,355 person-years of follow-up during the study period. The THIN database contributed 34.4% of the study population and PEDIANET contributed 0.2% (**Table 2**). The age and gender ratios for the children included in the SCCS analyses were similar between the databases (**Table 3**). The numbers of children exposed to wP and aP differed between the databases due to different periods for data availability and different dates for the wP to aP vaccine switch.

3.2. Incidence rates for risk outcomes

The highest number of events were recorded for fever (793,591 cases), followed by convulsions (104,059), persistent crying (29,768), ISR (19,241), HHE (5,898), and somnolence (2,562) (**Table 3**).

IRs for fever varied particularly in family paediatricians databases, e.g., PEDIANET 489.8 (95% CI 483.1; 496.5) and BIFAP 183.6 (95% CI 182.6; 184.7) and were lower in hospital databases (8.6 (95% CI: 8.5; 8.6)) than in the primary care databases (96.9 (95% CI: 96.7; 97.1)). The overall IR for convulsions was 7.6 (95% CI: 7.6; 7.7) and the IR was higher in hospital databases (IR=12.9 (95% CI 12.8; 13.0) than in primary care databases (IR=3.6 (95% CI: 3.5; 3.6) (**Table 4**). The overall IR for persistent crying was 3.9 (95% CI 3.8; 3.9), for

injection-site reactions 2.2 (95% CI 2.1; 2.2), for HHE 0.4 (95% CI 0.4; 0.4) and for somnolence 0.3 (95% CI 0.3; 0.3).

The hospital databases (AUH, SSI) could not be used to estimate injection-site reactions, somnolence, or persistent crying. SIDIAP could not be used for persistent crying analyses, as there were no ICD-10 codes for this event. However, the other primary care databases either had free-text or more detailed codes.

The IRs for persistent crying, HHE, ISR, and somnolence were highest among infants and decreased after the first six months of life. The IRs for convulsions were highest in the hospital-based systems in Denmark where they peaked at around 18 months of age. The highest incidence for fever was recorded for children at around 18 months of age, in all PC databases. In all databases the IRs for all events were higher in the risk periods than in the non-risk periods (**Table 4**).

3.3. Self-controlled case series analyses

We included 793,591 cases of fever, 104,059 cases of febrile or afebrile convulsions/seizures, 29,768 cases of persistent crying, 19,241 cases of injection-site reactions, 5,898, cases of HHE, and 2,562 cases of somnolence in the SCCS analyses (**Table 4**). Only RCGP RSC, THIN and BIFAP had data for children exposed to wP vaccine (**Table 4**). In these databases with information on wP and aP exposure, 11.51% of cases who had ≥1 risk event had been exposed to wP and 50.2% to aP (**Table 4**).

The pooled, age and healthy vaccinee period adjusted IRRs for risk versus non-risk periods were higher for wP than aP for all doses for persistent crying, fever, and injection-site reactions and for HHE the IIRs were lower IRRs for wP than aP. The IRs for somnolence were higher for wP only for dose 1 and 3 compared with those for aP. IRRs for convulsions are lower for wP than for aP for all doses (**Figures 2-7**). The results were statistically significant for persistent crying and injection-site reactions.

4. Discussion

The results of this POC study show that healthcare databases in ADVANCE can be used to generate reliable estimates for IRs and IRRs for a range of safety events. We showed that all databases cannot and should not be treated the same, as there can be important differences in rates based on where the data originate, i.e. in a primary care or hospital setting. Some events do not generally lead to hospitalisation and therefore hospital databases cannot be used to estimate the incidence of these events reliably and some events generally lead to hospitalisation, so that primary care databases cannot be used to estimate the incidence of these events. Within the ADVANCE network, we included both primary care and hospital databases, which allowed us to estimate the incidences of different types of events.

The main objective of this proof of concept study was to compare our retrospective results with published findings, when possible (**Table 5**). In a Danish birth cohort study the IRs for febrile seizures were reported to be 2.92, 4.75 and 31.0 per 1000 person-years, within seven days after the first, second and third aP dose [14]. In our study we estimated the IRs for combined febrile and afebrile convulsions/seizures within three days after any aP dose to be 17.28 in the Danish hospital databases, which is within the range of the published data.

In a patient-reported survey, continuous crying for more than 3h after wP was reported in 1.5% children and 0.4% following aP vaccination [29]. We found that 0.05% of the children showed persistent crying within 24h following aP or wP vaccination; this lower rate is expected because not all persistent crying will be reported in clinical care.

In a SCCS study conducted using data for birth cohorts of children born between 2003 and 2006 from the GPRD database in the UK the risks were not estimated by dose, but for children who received at least one dose [12]. The risk windows differed since the GPRD study estimated risk for the day of vaccination separately whereas we took the first 24 hours after vaccination as our risk window. The same differences in risk window length and analysis

regarding the day of vaccination were also found for a Danish birth cohort study [14]. The results from two systematic reviews and two birth cohort database studies are summarised in **Table 5** and compared with our estimates [12-15].

This proof of concept study was designed to test the capacity of the ADVANCE system to perform safety studies for events known to be associated with pertussis vaccination. We demonstrated that we were able to extract, share and pool data and generate evidence. In spite of this success there are some limitations. First, due to lack of resources, we could not validate the outcomes against patient's dossiers, even when they were available. Alternative validation studies and approaches have been proposed and investigated, e.g., component analyses, but future use of the system, especially when considering rare serious events, should have sufficient funding to enable validation of patients' dossiers [30]. We also demonstrated that primary care data sources are better suited to analyse less severe reactogenicity events compared with hospital databases, even if the absolute risks could be underestimated. If estimates of the absolute risks for these outcomes are need, secondary care databases should be complemented by primary data collection. In contrast, secondary care databases could be better situated for more severe outcomes that may not be recorded in primary care databases, since the children go directly to hospital. Injection-site reaction events are difficult to capture with electronic healthcare databases because the cause of the skin reaction is generally not recorded. Hence, we identified local skin reaction events that occurred in the risk window following vaccination in the SCCS. Therefore, the event 'injection-site reaction' was defined through all local skin reactions and symptoms with a temporal association with vaccination, not necessarily a causal association.

Second, we estimated risk windows based on vaccine prescriptions/administrations recorded in the databases. When using prescription databases, errors may occur due to delayed administration so that the date indicated in the database may not be the administration date.

This will have a greater impact on outcomes with shorter risk windows. It may be important to perform validation studies to assess the accuracy between date of vaccine recording and its administration.

5. Conclusions

We demonstrated the feasibility of generating vaccine safety data based on secondary use of electronic health data from various databases in a distributed healthcare database network in Europe. As expected in Europe, the databases were heterogeneous, which emphasises the opportunities and synergies that could be created by working with common methods and protocols and data sharing, since some databases may be more appropriate for estimating certain outcomes than others. The quantification of the heterogeneity between databases is a pre-requisite for generating reliable evidence that is needed to inform future vaccine B/R monitoring and assessments.

Disclaimer: The results described in this publication are from the proof of concept studies conducted as part of the IMI ADVANCE project with the aim of testing the methodological aspects of the design, conduct and reporting of studies for vaccine benefit-risk monitoring activities. The results presented relate solely to the methodological testing and are not intended to inform regulatory or clinical decisions on the benefits and risks of the exposures under investigation. This warning should accompany any use of the results from these studies and they should be used accordingly. The views expressed in this article are the personal views of the authors and should not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organisations with which the authors are affiliated.

Funding source

The Innovative Medicines Initiative Joint Undertaking funded this project under ADVANCE grant agreement n° 115557, resources of which were composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and in kind contributions from EFPIA member companies.

Conflicts of interest

Caitlin Dodd, Talita Duarte-Salles, Gino Picelli, Lara Tramontan, Giorgia Danieli, Ana Correa, Chris McGee, Elisa Martín-Merino, Consuelo Huerta, Hanne-Dorthe Emborg, Kaatje Bollaerts, Klara Berencsi declared no conflicts of interest. Daniel Weibel declared personal fees from GSK outside the submitted work. Olivia Mahaux, Francois Haguinet and Vincent Bauchau declared that they are employed by GSK and hold shares from GSK. Lina Titievsky declared that she is employed Pfizer and holds stocks from Pfizer. Miriam Sturkenboom declared that she has received grants from Novartis, CDC and the Bill & Melinda Gates Foundation outside the submitted work.

Acknowledgments

We would like to thank to the following persons who contributed to the work presented in this publication but did not satisfy the ICMJE authorship criteria: Alena Khromava, Linda Levesque, Denis Macina, Sandrine Gilhet-Mailfait (Sanofi Pasteur, Toronto, ON, Canada); Piotr Kramarz (European Center for Disease Prevention and Control, Solna, Sweden); Eduard Ledent, Maxwell Gough, Victoria Abbing-Karahagopian (GSK, Wavre, Belgium); Raphaele Roten, Jan Cleerbout, Bart Spiessens (Janssen Vaccines and Prevention B.V., Bern, Switzerland); Peter Rijnbeek, Maria de Ridder, Mees Mosseveld, Marius Gheorghe, Benedikt Becker (Erasmus University Medical Center, Rotterdam, Netherlands); Lisen Arnheim-Dahlstroem (Karolinska Institutet, Stockholm, Sweden); Rosa Gini (Agenzia regionale di sanità della Toscana, Florence, Italy); John Weil (Takeda, Hoofddorp, The Netherlands); Marianne van der Sande, Nicoline van der Maas (RIVM, Bilthoven, The Netherlands); Suzie Seabrooke (Medicines and Healthcare Products Regulatory Agency, London, UK), Simon de Lusignan, Rachel Byford, Mariya Hriskova, Filipa Ferreira, Ivelina Yonova (University of Surrey, Guildford, Surrey, UK); Myint Tin Tin Htar (Pfizer, Paris, France).

We would also like to acknowledge medical writing and editorial assistance from Margaret Haugh (MediCom Consult, Villeurbanne, France).

References

[1] Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011;343:d3908.

[2] Trifiro G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275:551-61.

[3] Sturkenboom M, Bahri P, Chiucchiuini A, Grove Krause T, S. H, Khromava A, et al. Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. Vaccine. 2018;Paper 1 in ADVANCE supplement.

[4] Sturkenboom M, van der Aa L, Bollaerts K, Emborg HD, Ferreira G, Gino R, et al. The ADVANCE distributed network system for evidence generation on vaccines coverage, benefits and risks based on electronic health care data. Vaccine. 2018;Paper 2 in supplement.

[5] Bollaerts K, Ledent E, de Smedt T, Weibel D, Emborg HD, Correa A, et al. ADVANCE system testing: benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and cohort modelling. Vaccine. 2018;Paper 9 in this supplement.

[6] Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25:1768-97.

[7] Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228-35.

[8] Sturkenboom M, Weibel D, van der Aa L, Braeye T, Gheorge M, Becker B, et al. ADVANCE database characterization and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of vaccinations. Vaccine. 2018;Paper 3 in Supplement.

[9] ADVANCE. D3.4 Catalogue and meta-profiles of data sources for vaccine benefit-risk monitoring. Available at: http://www.advance-

vaccines.eu/app/archivos/publicacion/18/ADVANCE_D3_4_WebCatalogue_Supplementary%20(Public).pdf. Accessed on: 25 October 2018.

[10] Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, et al. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016;6:e011092.

[11] Emborg HD, Berensci K, Braeye T, Bauwens J, Bollaerts K, Correa A, et al. ADVANCE system testing: can coverage of pertussis vaccination be estimated in EU countries using electronic health data: an example. Vaccine. 2018;Paper 4 in Supplement.

[12] Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28:7215-20.

[13] Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21:2003-14.

[14] Sun Y, Christensen J, Hviid A, Li J, Vedsted P, Olsen J, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. JAMA. 2012;307:823-31.

[15] Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014:CD001478.

[16] Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22:557-62.

[17] Bonhoeffer J, Vermeer P, Halperin S, Kempe A, Music S, Shindman J, et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22:586-91.

376 [18] Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al.
377 Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in
378 early childhood: case definition and guidelines for data collection, analysis, and presentation.
379 Vaccine. 2007;25:5875-81.
380 [19] Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, et al. A local reaction
381 at or near injection site: case definition and guidelines for collection, analysis, and
382 presentation of immunization safety data. Vaccine. 2008;26:6800-13.
383 [20] Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, et al. Swelling at or near
384 injection site: case definition and guidelines for collection, analysis and presentation of
385 immunization safety data. Vaccine. 2007;25:5858-74.
386 [21] Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al. Fever as an adverse
387 event following immunization: case definition and guidelines of data collection, analysis, and
388 presentation. Vaccine. 2004;22:551-6.
389 [22] de Lusignan S. Codes, classifications, terminologies and nomenclatures: definition,
390 development and application in practice. Inform Prim Care. 2005;13:65-70.
391 [23] Becker BFH, Avillach P, Romio S, van Mulligen EM, Weibel D, Sturkenboom M, et al.
392 CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE
393 project. Pharmacoepidemiol Drug Saf. 2017;26(8):998-1005.
394 [24] ADVANCE. D5.9 White paper, WP5 – Proof-of-concept studies of a framework to
395 perform vaccine benefit-risk monitoring. Available at: http://www.advance-
396 vaccines.eu/app/archivos/publicacion/62/D5.9_whitepaperWP5_V1_submitted_20180202.pdf
397 . Accessed on: 25 October 2018.
398 [25] ADVANCE. CodeMapper website (restricted access). Available at:
399 https://euadr.erasmusmc.nl/CodeMapper. Accessed on: 17 June 2017.

[26] Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131:373-5.

[27] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.

[28] EU PAS Register. ADVANCE POC I Risk. Available at: http://www.encepp.eu/encepp/viewResource.htm?id=21721. Accessed on: 16 August 2018.

[29] David S, Vermeer-de Bondt PE, van der Maas NA. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. Vaccine. 2008;26:5883-7.

[30] Gini R, Dodd C, Bollaerts K, Bartolini C, Roberto G, Huerta-Alvarez C, et al. Quantifying outcome misclassification in multi-database studies: the case study of pertussis in the ADVANCE project. Vaccine. 2018;Manuscript 8 in this special issue.

Table 1: Summary of participating database characteristics

	Country	Source/Type of data	Study period covered (years)	Date of wP to aP switch
AUH[1]	Denmark	Hospital, out- and inpatient diagnoses	2002 – 2015	1997
SSI[2]	Denmark	Hospital, out- and inpatient diagnoses	2000 – 2014	1997
RCGP RSC[3]	UK	GP	1990- 2015	October 2004
THIN[4]	UK	GP	1990-2015	October 2004
BIFAP[5]	Spain	GP and family paediatricians	2002 – 2015	1997 – 2004 wP and aP; 2005+ aP only
SIDIAP[6]	Spain	GP and family paediatricians	2006– 2015	1997 – 2004 wP and aP; 2005+ aP only
PEDIANET[7]	Italy	GP and family paediatrician	2006 – 2013	1996

[1] Aarhus University Hospital: https://www.ncbi.nlm.nih.gov/pubmed/21152254

[2] Statens Serum Institut: https://www.ssi.dk/English/RandD/Research%20areas/Epidemiology.aspx

[3] Royal College of General Practitioners: http://www.rcgp.org.uk/clinical-and-research/our-programmes/research-and-surveillance-centre.aspx

[4] The Health Improvement Network: https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database

[5] Base de Datos Para la Investigación Farmacoepidemiológica en Atención Primaria : http://www.bifap.org/summary.php

Información para el Desarrollo de la Investigación en Atención Primaria : http://www.sidiap.org/index.php/en

[7] Epidemiological Information for Clinical Research from an Italian Network of Family Paediatricians: http://pedianet.it/en

aP: acellular pertussis; wP: whole cell pertussis; GP: general practitioner

Table 2: Summary of type of database and numbers of individuals in each healthcare database

	Denmark		UK		Spain		Italy	
	AUH	SSI	RCGP RSC	THIN	BIFAP	SIDIAP	PEDIANET[1]	TOTAL
Type of database	Regional	National	National	National	Multiregional	Regional	Regional	
Total number of persons (all ages)	1,725,165	7,512,032	3,017,610	11,696,261	7,541,864	7,096,695	9708[2]	38,260,474
Number of persons with unknown birth month (all ages)	21	27	0	10,453,631[4]	0	0	0	10,453,679
Number of persons not having follow-up time in the study period (all age)	1,418,041	5,818,647	25,281	107,973	23	6'109'234	0	13,479,199
Number of persons with eligible data[3]	305,461	1,687,703	434,931	1,899,704[5]	756,536	992,812	9,547	23,184,035
Number of children (0-5 years) included in the final study cohort	271,949	1,203,365[6]	387,003	1,735,910	568,400	872,580	9,079	5,048,286

[1] PEDIANET includes only children 0-14 years of age, data linked with vaccination data were available only for the 2006 and 2007 cohorts; [2] with at least one day of follow-up between dose 1 and booster; [3] no exclusion if not registered within one month of age; [4]including total database cohort (on date 20 Jan 2017) as in common data model, independent of study period; [5] In the THIN database data protection regulations foresee that only children up to 15 years of age have birthdates with month and year recorded (i.e., valid birth date for the study), after 15 years of age only year of age will remain recorded in the database, therefore once a subject is 16 years old, they will be removed from the study due to insufficient birthdate information. This child cohort can provide valid data retrospectively until leaving the cohort at age 15 years. [6] In a last data cleaning step, due to database information entry changes over time, SSI data has been restricted to the period 2000 – 2014.

Table 3: Characteristics of cases included in the SCCS analyses. The numbers exposed to wP and aP correspond to vaccination at any time.

	Denmark		UK		Spain		Italy	
	AUH	**SSI**	**THIN**	**RCGP RSC**	**BIFAP**	**SIDIAP**	**PEDIANET**	**Total**
Fever								
Total events (n)	8,514	42,585	396,442	72,375	112,207	140,771	20,697	793,591
Mean age (years)	1.79	1.81	2.32	2.36	2.27	2.46	2.86	2.33
Male (%)	54.3	55.6	52.4	52.2	52.2	52.7	51.8	52.6
Exposed to wP (n)	0	0	85,491	10,226	1,290	0	0	97,007
Exposed to aP (n)	6,561	33,725	125,681	32,338	75,663	99,397	5,012	378,377
Febrile and afebrile convulsions/seizures								
Total events (n)	13,869	62,973	11,602	7,087	2,114	6,247	167	104,059
Mean age (years)	1.97	1.93	2.46	2.28	1.95	2.04	2.41	2.04
Male (%)	56.2	56.1	53.5	53.9	55.9	55.2	60.3	55.5
Exposed to wP (n)	0	0	3,431	1,648	26	0	0	5,105
Exposed to aP (n)	8,158	41,211	2,627	2,462	1,661	4,865	103	60,187
Persistent Crying								
Total events (n)	0	0	11,468	4,167	13,662	0	471	29,768
Mean age (years)	NA	NA	0.83	0.77	0.83	NA	1.16	0.83
Male (%)	NA	NA	53.2	53.9	53.7	NA	53.3	53.5
Exposed to wP (n)c	0	0	3,380	630	233	0	0	4,243
Exposed to aP (n)	0	0	6,554	2,937	12,901	0	353	22,745
Injection-site reaction								
Total events (n)	448	2,296	10,380	1,421	1,571	2,995	130	19,241
Mean age (years)	2.37	2.11	2.03	2.13	2.33	2.57	3.35	2.23
Male (%)	57.38	53.88	55.97	54.43	51.87	54.09	61.42	54.73
Exposed to wP (n)	0	0	2,589	272	17	0	0	2,878
Exposed to aP (n)	264	1,839	5,049	751	1,325	2,659	110	12,006
Hypotonic hypo-responsive episode								

	Denmark		UK		Spain		Italy	
	AUH	**SSI**	**THIN**	**RCGP RSC**	**BIFAP**	**SIDIAP**	**PEDIANET**	**Total**
Total events (n)	233	1,225	2,897	373	552	554	64	5,898
Mean age (years)	1.16	1.19	2.38	2.29	1.81	2.03	2.74	2.01
Male (%)	42.8	50.3	53.9	53.4	59.3	56.1	58.7	53.9
Exposed to wP (n)	0	0	1,198	111	9	0	0	1,318
Exposed to aP (n)	198	1,097	786	157	485	507	55	3,285
Somnolence								
Total events (n)	15	72	2037	300	66	61	11	2,562
Mean age (years)	2.64	2.74	1.79	1.88	2.23	2.53	1.72	1.89
Male (%)	26.7	38.7	51.6	52	51.5	53.1	36.4	51.2
Exposed to wP (n)	0	0	834	65	1	0	0	891
Exposed to aP (n)	7	55	830	175	59	58	9	1,193

436

437

Table 4: Summary of number of events and incidence rates (IRs) per 1000 person-years (PY) for safety outcomes after any dose of either wP or aP vaccine, by database (DB), type of database (primary care (PC) or hospital) and overall

	Non-risk period			Risk period			Overall (non-risk+risk period)
	Number of events	**PY**	**IR/1000PY (95% CI)**	**Number of events**	**PY**	**IR/1000PY (95% CI)**	**IR/1000PY (95% CI)**
Fever							
BIFAP	110,719	601,535	184.1 (183; 185.2)	1,488	9,546	155.9 (148.1; 164)	183.6 (182.6; 184.7)
SIDIAP	139,083	1,451,435	95.8 (95.3; 96.3)	1,688	17,465	96.7 (92.1; 101.4)	95.8 (95.3; 96.3)
RCGP RSC	71,831	1,006,079	71.4 (70.9; 71.9)	544	6,060	89.8 (82.4; 97.6)	71.5 (71; 72)
THIN	393,135	4,501,524	87.3 (87.1; 87.6)	3,307	28,911	114.4 (110.5; 118.4)	87.5 (87.2; 87.8)
PEDIANET	20,626	42,008	491 (484.3; 497.8)	71	252	281.9 (220.2; 355.6)	489.8 (483.1; 496.5)
PC DBs*	**735,394**	**7,602,198**	**96.7 (96.5; 97)**	**7,098**	**62,235**	**114.1 (111.4; 116.7)**	**96.9 (96.7; 97.1)**
AUH	8,362	967,669	8.6 (8.5; 8.8)	152	5487	27.7 (23.5; 32.5)	8.8 (8.6; 8.9)
SSI	41,964	4,969,111	8.4 (8.4; 8.5)	621	28,655	21.7 (20; 23.5)	8.5 (8.4; 8.6)
Hospital DS**	**50,326**	**5,936,780**	**8.5 (8.4; 8.6)**	**773**	**34,142**	**22.6 (21.1; 24.3)**	**8.56 (8.5; 8.6)**
Overall	**785,720**	**13,538,978**	**58.0 (57.9; 58.2)**	**7,871**	**96,377**	**81.7 (79.9; 83.5)**	**58.2 (58.1; 58.3)**
Febrile and afebrile convulsions/seizures							
BIFAP	2,088	601,535	3.5 (3.3; 3.6)	26	9,546	2.7 (1.8; 4)	3.5 (3.3; 3.6)
SIDIAP	6,121	1,451,435	4.2 (4.1; 4.3)	126	17,465	7.2 (6; 8.6)	4.3 (4.2; 4.4)
RCGP RSC	7,057	1,006,079	7 (6.9; 7.2)	30	6,060	5 (3.3; 7.1)	7 (6.8; 7.2)

	Non-risk period			Risk period			Overall (non-risk+risk period)
	Number of events	**PY**	**IR/1000PY (95% CI)**	**Number of events**	**PY**	**IR/1000PY (95% CI)**	**IR/1000PY (95% CI)**
THIN	11,515	4,501,524	2.6 (2.5; 2.6)	87	28,911	3 (2.4; 3.7)	2.6 (2.5; 2.6)
PEDIANET	166	42,008	4 (3.4; 4.6)	1	252	4 (0.1; 22.1)	4 (3.4; 4.6)
PC DBs*	**26,947**	**7,602,198**	**3.5 (3.5; 3.6)**	**270**	**62,235**	**4.3 (3.8; 4.9)**	**3.55 (3.5; 3.6)**
AUH	13,732	967,669	14.2 (14; 14.4)	137	5,487	25 (21; 29.5)	14.3 (14; 14.5)
SSI	62,520	4,969,111	12.6 (12.5; 12.7)	453	28,655	15.8 (14.4; 17.3)	12.6 (12.5; 12.7)
Hospital DBs**	**76,252**	**5,936,780**	**12.8 (12.8; 12.9)**	**590**	**34,142**	**17.3 (15.9; 18.7)**	**12.87 (12.8; 13)**
Overall	**103,199**	**13,538,978**	**7.6 (7.6; 7.7)**	**860**	**96,377**	**8.9 (8.3; 9.5)**	**7.6 (7.6; 7.7)**
Persistent crying, irritability							
BIFAP	13,425	606,306	22.1 (21.8; 22.5)	237	4,775	49.6 (43.5; 56.4)	22.4 (22; 22.7)
RCGP RSC	4,011	1,009,126	4.0 (3.9; 4.1)	156	3,013	51.8 (44; 60.6)	4.1 (4; 4.2)
THIN	10,976	4515621	2.4 (2.4; 2.5)	492	14,422	34.1 (31.2; 37.3)	2.5 (2.5; 2.6)
PEDIANET	468	42,134	11.1 (10.1; 12.2)	3	126	23.8 (4.9; 69.6)	11.2 (10.2; 12.2)
PC DBs*	**28,880**	**6.173.187**	**3.8 (3.7; 3.8)**	**888**	**31,071**	**28.6 (26.7; 30.5)**	**3.9 (3.8; 3.9)**
Injection-site reactions							
BIFAP	1,441	591,994	2.4 (2.3; 2.6)	130	19,088	6.8 (5.7; 8.1)	2.6 (2.5; 2.7)
SIDIAP	2,547	1,433,980	1.8 (1.7; 1.9)	448	34,921	12.8 (11.7; 14.1)	2 (2; 2.1)
RCGP RSC	1,334	999,911	1.3 (1.3; 1.4)	87	12,228	7.1 (5.7; 8.8)	1.4 (1.3; 1.5)

	Non-risk period			Risk period			Overall (non-risk+risk period)
	Number of events	**PY**	**IR/1000PY (95% CI)**	**Number of events**	**PY**	**IR/1000PY (95% CI)**	**IR/1000PY (95% CI)**
THIN	9,680	4,472,440	2.2 (2.1; 2.2)	700	58,013	12.1 (11.2; 13.0)	2.3 (2.3; 2.3)
PEDIANET	128	41,756	3.1 (2.6; 3.6)	2	504	4 (0.5; 14.4)	3.1 (2.6; 3.7)
PC DBs*	**15,130**	**7,539,697**	**2 (2; 2)**	**1,367**	**124,754**	**11 (10.4; 11.6)**	**2.2 (2.1; 2.2)**
Hypotonic hypo-responsive episode							
BIFAP	451	603,920	0.8 (0.7; 0.8)	101	7,161	14.1 (11.5; 17.1)	0.9 (0.8; 1)
SIDIAP	483	1,455,800	0.3 (0.3; 0.4)	71	13,101	5.4 (4.2; 6.8)	0.4 (0.4; 0.4)
RCGP RSC	371	1,007,605	0.4 (0.3; 0.4)	2	4,534	0.4 (0.1; 1.6)	0.4 (0.3; 0.4)
THIN	2,858	4,508,769	0.6 (0.6; 0.7)	39	21,661	1.8 (1.3; 2.5)	0.6 (0.6; 0.7)
PEDIANET	64	42,071	1.5 (1.2; 1.9)	0	189	0 (0; 19.5)	1.5 (1.2; 1.9)
PC DBs*	**4,227**	**7,617,782**	**0.6 (0.5; 0.6)**	**213**	**46,646**	**4.6 (4; 5.2)**	**0.6 (0.6; 0.6)**
AUH	228	969,041	0.2 (0.2; 0.3)	5	4,115	1.2 (0.4; 2.8)	0.2 (0.2; 0.3)
SSI	1,208	4,976,276	0.2 (0.2; 0.3)	17	21,490	0.8 (0.5; 1.3)	0.3 (0.2; 0.3)
Hospital DBs**	**1,436**	**5,945,317**	**0.2 (0.2; 0.3)**	**22**	**25,606**	**0.9 (0.5; 1.3)**	**0.2 (0.2; 0.3)**
Overall	**5,663**	**13,563,100**	**0.4 (0.4; 0.4)**	**235**	**72,252**	**3.3 (2.8; 3.7)**	**0.4 (0.4; 0.4)**
Somnolence							
BIFAP	62	603,920	0.1 (0.1; 0.1)	4	7,161	0.6 (0.2; 1.4)	0.1 (0.1; 0.1)
SIDIAP	60	1,455,800	0 (0; 0.1)	1	13,101	0.1 (0; 0.4)	0 (0; 0.1)

	Non-risk period			Risk period			Overall (non-risk+risk period)
	Number of events	**PY**	**IR/1000PY (95% CI)**	**Number of events**	**PY**	**IR/1000PY (95% CI)**	**IR/1000PY (95% CI)**
RCGP RSC	288	1,007,605	0.3 (0.3; 0.3)	12	4,534	2.7 (1.4; 4.6)	0.3 (0.3; 0.3)
THIN	1,976	4,508,769	0.4 (0.4; 0.5)	61	21,661	2.8 (2.2; 3.6)	0.5 (0.4; 0.5)
PEDIANET	10	42,071	0.2 (0.1; 0.4)	1	189	5.3 (0.1; 29.5)	0.3 (0.1; 0.5)
PC DBs*	**2,396**	**7.617.783**	**0.1 (0.3; 0.3)**	**79**	**46.646**	**1.7 (1.3; 2.1)**	**0.3 (0.3; 0.3)**

440 * Overall estimate including primary care (PC) databases: BIFAP, SIDIAP, RCGP RSC, THIN and PEDIANET

441 ** Overall estimates including hospital databases: AUH and SSI

442

443 **Table 5:** Comparison of estimated and published incidence rate ratios (IRRs) for all risk outcomes (except somnolence)

	Estimates from this study		Zhang 2014 [15]		Jefferson 2003 [13]		Andrews 2010 [12]		Sun 2012 [14]	
	Risk window	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**
Persistent crying										
wP all D					2-72h	12.59 (1.91;83.00)	0d	6.51 (5.53; 7.66)		
							1-3d	1.44 (1.18; 1.75)		
wP D1	0-24h	4.85 (4.43; 5.32)								
wP D2	0-24h	2.36 (1.17; 4.73)								
wP D3	0-24h	2.11 (1.80;2.47)								
aP all D					2-72h	1.23 (0.73; 2.06)	0d	3.09 (2.49; 3.85)		
							1-3d	0.77 (0.60; 0.99)		
aP D1	0-24h	1.99 (1.66; 2.40)		1.29 (0.71; 2.34)						
aP D2	0-24h	1.16 (0.88;1.53)		1.08 (0.83; 1.40)						
aP D3	0-24h	1.29 (0.75;2.21)		1.06 (0.66; 1.68)						
Hypotonic-hypo-responsive episode										
wP all D					0-48h	3.22 (0.39; 26.78)	0d	1.22 (0.30; 4.96)[c]		
							1-3d	0.62 (0.20; 1.99)[c]		
wP D1	0-48h	1.70 (0.99; 2.94))								
wP D2	0-48h	0.58 (0.38; 0.87)								
wP D3	0-48h	1.28 (0.94; 1.74)								
aP all D				0.29 (0.02; 5.13)	0-48h	0.29 (0.04; 2.28)	0d	3.22 (1.30; 7.98);		
							1-3d	1.56 (0.71; 3.39)		

	Estimates from this study		Zhang 2014 [15]		Jefferson 2003 [13]		Andrews 2010 [12]		Sun 2012 [14]	
	Risk window	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**
aP D1	0-48h	2.80 (1.52; 2.16)								
aP D2	0-48h	1.73 (0.86; 3.48)								
aP D3	0-48h	1.75 (0.79; 387)								
Fever										
wP all D							0d	1.84 (1.30; 2.61)		
							1-3d	2.28 (1.90; 2.75)		
wP D1	0-72h	1.42 (0.78; 2.60)[a]			0-72h[b]	33.29 (28.48; 38.91)				
wP D2	0-72h	1.40 (1.23; 1.59)								
wP D3	0-72h	2.01 (1.67; 2.41)								
aP all D							0d	1.65 (1.19; 2.30)		
							1-3d	0.83 (0.64; 1.09)		
aP D1	0-72h	1.09 (0.99; 1.21)		1.18 (0.73; 1.90)	0-72h[b]	1.10 (0.79; 1.53)				
aP D2	0-72h	0.94 (0.87;1.02)		1.00 (0.91; 1.11)						
aP D3		1.12 (0.95; 1.33)		1.03 (0.94; 1.13)						
Convulsions										
wP all D					0-72h	1.04 (0.16; 6.72)	0d	4.14 (1.92; 8.92)		
							1-3d	1.37 (0.63; 2.95)		
wP D1	0-72h	1.20 (0.70; 2.05)								
wP D2	0-72h	0.85 (0.42; 1.72)								
wP D3	0-72h	1.34 (0.50; 3.56)								
aP all D				0.44 (0.12; 1.69)	0-72h	1.00 (0.27; 3.74)	0d	2.05 (0.65; 6.46)		

	Estimates from this study		Zhang 2014 [15]		Jefferson 2003 [13]		Andrews 2010 [12]		Sun 2012 [14]	
	Risk window	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**	**Risk window**	**IRR (95% CI)**
							1-3d	0.45 (0.11; 1.83)		
aP D1	0-72h	1.53 (1.02; 2.30)							0d	6.49 (3.10-13.61)
									1-3d	1.47 (0.62-3.50)
aP D2	0-72h	0.99 (0.78; 1.26)							0d	3.97 (2.20-7.16);
									1-3d	1.52 (0.88-2.64)
aP D3	0-72h	1.41 (0.98; 2.03)							0d	1.07 (0.73-1.57);
									1-3d	0.89 (0.70-1.14)
Injection-site reactions										
wP D1	0-7d	2.27 (1.73; 2.99)			0-72h	11.49 (8.68; 15.22)[d]				
wP D2	0-7d	2.34 (2.09; 2.62)								
wP D3	0-7d	2.62 (1.69; 4.06)								
aP D1	0-7d	1.37 (1.12; 1.67)		1.29 (0.62; 2.68)	0-72h	0.99 (0.67; 1.48) [d]				
aP D2	0-7d	1.77 (1.08; 2.89)		2.08 (0.54; 8.01)						
aP D3	0-7d	1.54 (1.11; 2.14)		1.13 (1.07; 1.20)						

444

445 [a] Temperature ≥38°C; [b] Temperature >38°C; [c] Apnoea/collapse/cyanosis/pallor; [d] Swelling/induration

446

447

Figure legends

Figure 1: Follow-up periods used in the SCCS analyses

Figure 2: Incidence rate ratios for fever in the self-controlled case series analyses. IRRs were adjusted for age in months and for the healthy vaccinee period

Figure 3: Incidence rate ratios for febrile and afebrile convulsions/seizures in the self-controlled case series analyses. IRRs were adjusted for age in months and for the healthy vaccinee period

Figure 4: Incidence rate ratios for persistent crying, irritability in the self-controlled case series analyses. IRRs were adjusted for age in months and for the healthy vaccinee period

Figure 5: Incidence rate ratios for injection-site reactions in the self-controlled case series analyses. IRRs were adjusted for age in months and for the healthy vaccinee period

Figure 6: Incidence rate ratios for hypotonic hypo-responsive episodes in the self-controlled case series analyses. IRRs were adjusted for age in months and for the healthy vaccinee period

Figure 7: Incidence rate ratios for somnolence in the self-controlled case series analyses. IRRs were adjusted for age in months and for the healthy vaccinee period

Figure 1



Non risk period (control period)

Exclusion of week before vaccination to account for a potential healthy vaccinee effect

Risk period

Figure 2



o influential IRR which has been excluded from the pooled estimate

Figure 3


Database
Incidence Rate Ratio [95% CI]
Whole-cell pertussis vaccine
Dose 1
UK (THIN) 0.95 [0.61, 1.48]
UK (RCGP) 1.65 [0.63, 4.29]
Pooled 1.20 [0.70, 2.05]
(Heterogeneity: Q = 4.2 , p-value = 0.04 ; I2 = 76 %)
Dose 2
UK (THIN) 1.13 [0.75, 1.71]
UK (RCGP) 0.54 [0.13, 2.25]
Pooled 0.85 [0.42, 1.72]
(Heterogeneity: Q = 3.8 , p-value = 0.05 ; I2 = 74 %)
Dose 3
UK (THIN) 0.82 [0.50, 1.36]
UK (RCGP) 2.24 [0.98, 5.11]
Pooled 1.34 [0.50, 3.56]
(Heterogeneity: Q = 16.4 , p-value = 0 ; I2 = 94 %)
Acellular pertussis vaccine
Dose 1
UK (THIN) 1.26 [0.87, 1.84]
UK (RCGP) 1.71 [0.98, 3.01]
Spain (SIDIAP) 2.77 [2.09, 3.66]
Spain (BIFAP) 2.10 [1.20, 3.69]
Italy (PEDIANET) 0.56 [0.07, 4.20]
Denmark (SSI) 1.00 [0.83, 1.21]
Pooled 1.49 [0.96, 2.32]
(Heterogeneity: Q = 152.4 , p-value = 0 ; I2 = 97 %)
Dose 2
UK (THIN) 0.85 [0.54, 1.35]
UK (RCGP) 0.56 [0.23, 1.38]
Spain (SIDIAP) 1.41 [0.98, 2.01]
Spain (BIFAP) 1.12 [0.52, 2.42]
Italy (PEDIANET) 1.49 [0.43, 5.19]
Denmark (SSI) 0.86 [0.73, 1.01]
Pooled 0.98 [0.77, 1.26]
(Heterogeneity: Q = 33.1 , p-value = 0 ; I2 = 85 %)
Dose 3
UK (THIN) 1.17 [0.77, 1.78]
UK (RCGP) 0.95 [0.47, 1.90]
Spain (SIDIAP) 2.29 [1.70, 3.09]
Spain (BIFAP) 1.98 [1.05, 3.74]
Italy (PEDIANET) 1.57 [0.53, 4.71]
Denmark (SSI) 0.99 [0.91, 1.07]
Pooled 1.40 [0.96, 2.06]
(Heterogeneity: Q = 133.4 , p-value = 0 ; I2 = 96 %)
0
1.75
3.5
5.25
7
IRR

Figure 4


Database
Incidence Rate Ratio [95% CI]
Whole-cell pertussis vaccine
Dose 1
UK (THIN) 4.87 [4.00, 5.92]
UK (RCGP) 4.76 [2.91, 7.79]
Pooled 4.85 [4.43, 5.32]
(Heterogeneity: Q = 0 , p-value = 0.87 ; I2 = 0 %)
Dose 2
UK (THIN) 3.27 [2.54, 4.21]
UK (RCGP) 1.61 [0.71, 3.63]
Pooled 2.36 [1.17, 4.73]
(Heterogeneity: Q = 10.7 , p-value = 0 ; I2 = 91 %)
Dose 3
UK (THIN) 2.14 [1.52, 3.01]
UK (RCGP) 1.95 [0.85, 4.44]
Pooled 2.11 [1.80, 2.47]
(Heterogeneity: Q = 0.2 , p-value = 0.68 ; I2 = 0 %)
Acellular pertussis vaccine
Dose 1
UK (THIN) 2.26 [1.91, 2.67]
UK (RCGP) 2.06 [1.59, 2.68]
Spain (BIFAP) ° 1.24 [1.04, 1.48]
Italy (PEDIANET) 1.29 [0.60, 2.77]
Pooled 1.99 [1.66, 2.40]
(Heterogeneity: Q = 8.6 , p-value = 0.01 ; I2 = 77 %)
Dose 2
UK (THIN) 1.45 [1.14, 1.84]
UK (RCGP) 0.87 [0.57, 1.32]
Spain (BIFAP) 0.97 [0.76, 1.23]
Italy (PEDIANET) 1.56 [0.79, 3.08]
Pooled 1.16 [0.88, 1.53]
(Heterogeneity: Q = 32.7 , p-value = 0 ; I2 = 91 %)
Dose 3
UK (THIN) 1.66 [1.27, 2.18]
UK (RCGP) 2.33 [1.71, 3.18]
Spain (BIFAP) 0.75 [0.54, 1.03]
Italy (PEDIANET) 0.90 [0.40, 2.05]
Pooled 1.29 [0.75, 2.21]
(Heterogeneity: Q = 110.6 , p-value = 0 ; I2 = 97 %)
0
1.75
3.5
5.25
7
o influential IRR which has been excluded from the pooled estimate
IRR

Figure 5



o influential IRR which has been excluded from the pooled estimate

Figure 6


Database
Incidence Rate Ratio [95% CI]
Whole-cell pertussis vaccine
Dose 1
UK (THIN)
1.70 [0.99, 2.94]
Pooled
(Heterogeneity: Q = 0 , p-value = 1 ; I2 = 0 %)
1.70 [1.30, 2.24]
Dose 2
UK (THIN)
0.53 [0.22, 1.30]
UK (RCGP)
0.90 [0.11, 7.07]
Pooled
(Heterogeneity: Q = 0.9 , p-value = 0.36 ; I2 = 0 %)
0.58 [0.38, 0.87]
Dose 3
UK (THIN)
1.28 [0.69, 2.37]
Pooled
(Heterogeneity: Q = 0 , p-value = 1 ; I2 = 0 %)
1.28 [0.94, 1.74]
Acellular pertussis vaccine
Dose 1
UK (THIN)
1.75 [1.05, 2.90]
UK (RCGP)
1.87 [0.51, 6.86]
Spain (SIDIAP)
4.73 [3.17, 7.06]
Spain (BIFAP)
6.59 [4.79, 9.07]
Italy (PEDIANET)
3.19 [0.82, 12.41]
Denmark (SSI)
1.53 [1.00, 2.34]
Pooled
(Heterogeneity: Q = 160.1 , p-value = 0 ; I2 = 97 %)
2.84 [1.57, 5.15]
Dose 2
UK (THIN)
1.22 [0.67, 2.23]
Spain (SIDIAP)
3.08 [1.88, 5.03]
Spain (BIFAP)
3.33 [2.16, 5.15]
Denmark (SSI)
0.67 [0.34, 1.30]
Pooled
(Heterogeneity: Q = 84.5 , p-value = 0 ; I2 = 96 %)
1.72 [0.84, 3.49]
Dose 3
UK (THIN)
0.79 [0.36, 1.72]
Spain (SIDIAP)
4.66 [2.83, 7.69]
Spain (BIFAP)
4.10 [2.49, 6.77]
Italy (PEDIANET)
0.95 [0.12, 7.76]
Denmark (SSI)
0.95 [0.43, 2.10]
Pooled
(Heterogeneity: Q = 97.9 , p-value = 0 ; I2 = 96 %)
1.76 [0.80, 3.87]
0
1.75
3.5
5.25
7
IRR

Figure 7


Database
Incidence Rate Ratio [95% CI]
Whole-cell pertussis vaccine
Dose 1
UK (THIN)
2.82 [1.63, 4.86]
UK (RCGP)
10.89 [3.65, 32.46]
Pooled
5.42 [1.44, 20.38]
(Heterogeneity: Q = 18.9 , p-value = 0 ; I2 = 95 %)
Dose 2
UK (THIN)
1.03 [0.38, 2.80]
Pooled
1.03 [0.63, 1.70]
(Heterogeneity: Q = 0 , p-value = 1 ; I2 = 0 %)
Dose 3
UK (THIN)
1.88 [0.75, 4.69]
UK (RCGP)
2.76 [0.35, 22.02]
Pooled
2.00 [1.32, 3.04]
(Heterogeneity: Q = 0.4 , p-value = 0.51 ; I2 = 0 %)
Acellular pertussis vaccine
Dose 1
UK (THIN)
2.72 [1.76, 4.22]
UK (RCGP)
1.24 [0.29, 5.22]
Spain (SIDIAP)
1.54 [0.20, 11.68]
Spain (BIFAP)
9.90 [2.65, 36.97]
Italy (PEDIANET)
9.39 [0.93, 95.15]
Pooled
3.35 [1.63, 6.90]
(Heterogeneity: Q = 24.5 , p-value = 0 ; I2 = 84 %)
Dose 2
UK (THIN)
1.91 [1.00, 3.62]
UK (RCGP)
4.17 [1.45, 11.97]
Spain (BIFAP)
4.02 [0.52, 30.88]
Pooled
2.95 [1.60, 5.46]
(Heterogeneity: Q = 7.2 , p-value = 0.03 ; I2 = 72 %)
Dose 3
UK (THIN)
1.29 [0.47, 3.55]
Pooled
1.29 [0.78, 2.14]
(Heterogeneity: Q = 0 , p-value = 1 ; I2 = 0 %)
0
5
10
15
20
IRR

Supplemental Table 1

Click here to download Supplemental Files: ADVANCE Risk Online supplement Table 1.docx